The recent activities of globally recognised bio-tech firm, Bristol Myers Squibb (BMY) has raised significant attention. High profile ventures include a $400M AI-Driven deal for drug development, a $25M milestone payment for ALS treatment target discovery and partnering with Fangzhou in China. BMY's overall performance in the stock market has been strong, with one-year gains marking a 24% increase. Jefferies' 'buy' rating upgrade based on Cobenfy, a schizophrenia treatment drug, adds more credence to its prospects. In addition, their new CAR T cell therapies like Breyanzi were also approved by the U.S FDA for treating different types of lymphoma.
BMY's Q4 2024 earnings is highly anticipated, in light of consistent good performances, even beating expectations in some quarters. The company's recent dividend increment based on strong financial performance also holds promise for investors. The business outlook remains positive, backed by potential double-digit upside and high-dividend yields. The stock attractiveness is further bolstered by BMY's resilient attempt to handle its patent cliff and the perceived undervaluation of its stock. Lastly, BMY's strategic acquisitions and corporate collaborations such as the T-Cell Therapies agreement with Prime Medicine demonstrates its ongoing bid for growth and innovation in the biotech market.
Bristol-Myers Squibb BMY News Analytics from Thu, 14 Mar 2024 07:00:00 GMT to Sat, 21 Dec 2024 10:29:04 GMT - Rating 8 - Innovation 7 - Information 8 - Rumor -6
